- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RELIEF THERAPEUTICS HOLDING AG ADR Aktie jetzt für 0€ handeln | |||||
| 27.12.24 | Relief Therapeutics advances merger talks with Renexxion | 12 | Seeking Alpha | ||
| 27.12.24 | Relief Therapeutics Holding SA: Relief Therapeutics Provides Update on Potential Transaction with Renexxion | 427 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Merger
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
27.12.2024 / 07:00 CET/CEST
Relief Therapeutics... ► Artikel lesen | |
| 17.12.24 | Relief Therapeutics Holding SA - 15F-12G, Securities registration termination of foreign private issuers | 5 | SEC Filings | ||
| 16.12.24 | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 16.12.24 | Relief Therapeutics Holding SA: Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial | 331 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Study results
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
16.12.2024 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
| 14.12.24 | Relief Therapeutics beantragt Aussetzung der Berichtspflichten bei US-Börsenaufsicht | 21 | cash | ||
| 13.12.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations | 10.271 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
13-Dec-2024 / 23:00 CET/CEST
Release... ► Artikel lesen | |
| 12.11.24 | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 21 | SEC Filings | ||
| 11.11.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | 3.682 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
11-Nov-2024 / 07:00... ► Artikel lesen | |
| 05.11.24 | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 04.11.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger | 2.646 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Merger
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
04-Nov-2024 / 07:00 CET/CEST
Release of an... ► Artikel lesen | |
| 29.10.24 | Relief Therapeutics Holding SA: Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE | 318 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29.10.2024 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
| 25.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents | 4.509 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
25-Oct-2024 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 22.10.24 | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 8 | SEC Filings | ||
| 21.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment | 2.906 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Patent
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
21-Oct-2024... ► Artikel lesen | |
| 09.10.24 | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 24 | SEC Filings | ||
| 08.10.24 | Relief Therapeutics gains on proof-of-concept data for antimicrobial agent | 31 | Seeking Alpha | ||
| 08.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | 3.346 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
08-Oct-2024... ► Artikel lesen | |
| 04.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria | 6.560 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
04-Oct-2024 /... ► Artikel lesen | |
| 23.09.24 | Relief Therapeutics Receives $2M Milestone Payment Following FDA Approval | 10 | Contract Pharma |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REVIVE THERAPEUTICS | 0,001 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 43,000 | +6,09 % | SpringWorks Therapeutics jumps amid takeover speculation | ||
| ADMA BIOLOGICS | 18,560 | 0,00 % | ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? | ||
| QIAGEN | 44,095 | -0,20 % | Biotech Report: Evotec und Qiagen im Plus | (shareribs.com) Frankfurt / New York 09.01.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Hier konnten unter anderem Evotec und Qiagen zulegen. In den USA fand aufgrund eines... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,390 | -1,64 % | 2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy | ||
| RECURSION PHARMACEUTICALS | 6,880 | -5,30 % | Recursion Pharmaceuticals: Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More | REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539... ► Artikel lesen | |
| NUVALENT | 76,61 | -2,18 % | Nuvalent-Forschungschef verkauft Aktien im Wert von 197.853 US-Dollar | ||
| AVIDITY BIOSCIENCES | 29,460 | -1,44 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,020 | -12,25 % | Vera Therapeutics (NASDAQ:VERA) Stock Price Down 7.3% - Should You Sell? | ||
| TEMPUS AI | 37,520 | +0,13 % | Tempus AI (NASDAQ:TEM) Trading Down 3.6% Following Insider Selling | ||
| KYMERA THERAPEUTICS | 38,170 | -5,80 % | Analysts Issue Forecasts for KYMR FY2029 Earnings | ||
| HARMONY BIOSCIENCES | 33,860 | -1,93 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,840 | -31,25 % | Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1 | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).... ► Artikel lesen | |
| IMMUNOVANT | 23,480 | -0,70 % | Immunovant-Finanzchefin Eva Renee Barnett verkauft Aktien im Wert von 98.930 US-Dollar | ||
| BIONTECH | 119,40 | -0,50 % | BioTech-Rally 2025: Evotec, BioNTech, Vidac Pharma, Pfizer und Bayer sind auf der Kaufliste | Zwei Jahre tat sich nun fast gar nichts im BioTech-Sektor. Nicht einmal der in 2024 eingeläutete Zinssenkungstrend konnte die Investoren zu größeren Investments bewegen. Dafür haben die KI- und Hightech-Aktien... ► Artikel lesen |
Das Unternehmen RELIEF THERAPEUTICS HOLDING AG ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,107 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RELIEF THERAPEUTICS HOLDING AG ADR finden Sie auf Wallstreet Online.
